Biotech cell preservation and regenerative medicine
Strategic Profile
The company's patented anti-aging glycopeptide (AAGP) is based on a molecule found in nature and developed by a world-class research team, with the capability to help more cells survive longer. ProtoKinetix has partnered with IQVIA to accelerate clinical development and regulatory progress of PKX-001 in ocular conditions, specifically dry eye disease and age-related macular degeneration.
Cyborg Score Rationale
The company has a market cap of approximately $1.7M with negative trailing twelve-month earnings. ProtoKinetix has not developed a commercially viable product and has not generated revenue. Early-stage clinical development with minimal commercial traction poses substantial execution and capital risks.
Top Insights
Phase 1 clinical trial for PKX-001 for type 1 diabetes islet cell transplants at University of Alberta completed enrollment with achievement of primary safety objectives
ProtoKinetix partnered with a global pharmaceutical firm to develop a topical ocular drug for dry eye disease; company completed ocular irritation tests and pre-clinical trials with efficacy demonstrated, with upcoming FDA approval pathway for clinical trials
Testing in neural stem cells for cryopreservation has shown progress toward prolonging shelf life of donor blood and blood products
Company was incorporated in 1999 and rebranded from RJV Network to ProtoKinetix in July 2003
Named Competitors
Allergan/AbbVie Dry Eye Portfolio — Established dry eye disease treatments in established market
Rejuvenation Therapeutics Cell Preservation — Cell preservation and cryopreservation technologies
Novartis/Alcon Ophthalmology — Established ophthalmology treatments and drug development
Recent Developments
Phase 1 clinical trial completion for PKX-001 in Type 1 diabetes islet cell transplants reported with safety objectives achieved
Formulation development and pre-clinical efficacy testing for dry eye disease indications ongoing with pharmaceutical partner collaboration
Peer-reviewed research publication on AAGP for retinal precursor cell transplantation and vision restoration published in Journal of Tissue Engineering and Regenerative Medicine
Open the full interactive ProtoKinetix, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.